4.8 Review

Complement Inhibitors in Clinical Trials for Glomerular Diseases

期刊

FRONTIERS IN IMMUNOLOGY
卷 10, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2019.02166

关键词

inhibitors; clinical trials; glomerular disease; C3 glomerulopathy; complement; ANCA; aHUS

资金

  1. Collaborative Research Center (CRC) [SFB 1192]
  2. Deutsche Forschungsgemeinschaft (DFG)

向作者/读者索取更多资源

Defective complement action is a cause of several human glomerular diseases including atypical hemolytic uremic syndrome (aHUS), anti-neutrophil cytoplasmic antibody mediated vasculitis (ANCA), C3 glomerulopathy, IgA nephropathy, immune complex membranoproliferative glomerulonephritis, ischemic reperfusion injury, lupus nephritis, membranous nephropathy, and chronic transplant mediated glomerulopathy. Here we summarize ongoing clinical trials of complement inhibitors in nine glomerular diseases and show which inhibitors are used in trials for these renal disorders (http://clinicaltrials.gov).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据